KS-TEXTRON-AVIATION
10.7.2024 20:31:30 CEST | Business Wire | Press release
Textron Aviation today announced the delivery of the first Cessna SkyCourier twin-engine utility turboprop equipped with a Combi interior conversion option. The aircraft was delivered to Everts Air, an Alaskan-based Part 135 operator serving passenger, cargo and charter needs throughout Alaska. Everts also operates Part 121, providing cargo and on-demand charter throughout North, Central and South America, as well as the Caribbean Islands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240710876388/en/
Textron Aviation | Cessna SkyCourier Combi (Photo: Business Wire)
The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company.
“The Cessna SkyCourier’s new Combi option demonstrates the aircraft’s ability to meet the versatile mission profiles of our customers around the world,” said Lannie O’Bannion, senior vice president, Sales and Flight Operations. “We are grateful that longtime Cessna customers like Everts Air recognize the value in our products as business tools and their capability in serving customers.”
The Federal Aviation Administration (FAA) granted certification for the SkyCourier Combi interior configuration in May 2024. The recently certified option adds more flexibility to the 19-seat passenger variant of the aircraft by allowing operators to modify the interior to accommodate passengers and cargo at the same time. In addition to the existing gravel kit and full freighter conversion options, the Combi conversion expands the aircraft’s utility for diverse global markets and a wide variety of missions, catering to customers such as government bodies, law enforcement, armed forces, businesses and charitable groups.
The aircraft will join the Everts Air Alaska 135 fleet, which also includes a Cessna SkyCourier freighter variant and six Cessna Caravans.
“I look at the Cessna SkyCourier as a next generation aircraft for Bush Alaska,” said Robert W. Everts, owner of Everts Air. “The SkyCourier Combi will allow us to be flexible and serve the unique needs of citizens in remote communities. Along with offering the reliability of a Cessna, the aircraft is highly adaptable and the ultimate solution for air freight and passenger support in Alaska.”
About the Cessna SkyCourier
The Cessna SkyCourier twin-engine, high-wing turboprop offers a combination of performance and lower operating costs for air freight, commuter, and special mission operators. It’s available in both freighter and passenger variants. The 19-passenger variant includes separate crew and passenger doors for smooth boarding, a large baggage compartment and large cabin windows for natural light and views. The freighter variant features a flat floor cabin that is sized to handle up to three LD3 shipping containers with an impressive 6,000 pounds of payload capability. Both variants offer a large cargo door and single-point pressure refueling to enable faster turnarounds.
The aircraft is powered by two wing-mounted Pratt & Whitney PT6A-65SC turboprop engines and features the McCauley Propeller C779, a heavy-duty and reliable 110-inch aluminum four-blade propeller, which is full feathering with reversible pitch, designed to enhance the performance of the aircraft while hauling tremendous loads. The SkyCourier features Garmin G1000 NXi avionics and has a maximum cruise speed of more than 200 ktas. The SkyCourier has a 900-nautical-mile maximum range.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight. For more information, visit www.txtav.com | www.defense.txtav.com | www.scorpionjet.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, Textron Systems, and TRU Simulation. For more information, visit: www.textron.com.
Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710876388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom